吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

交易中 12-15 13:46:53 EST

120.66

+1.05

+0.87%

最高122.98	最低120.06	成交量266.89万
今开122.00	昨收119.61	日振幅2.44%
总市值1,497亿	流通市值1,494亿	总股本12.41亿
成交额3.24亿	换手率0.22%	流通股本12.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":120.655,"timestamp":1765824413342,"preClose":119.61,"halted":0,"volume":2668943,"delay":0,"floatShares":1238162880,"shares":1240679623,"eps":6.422841,"marketStatus":"交易中","change":1.045,"latestTime":"12-15 13:46:53 EST","open":122,"high":122.98,"low":120.06,"amount":323513513.020528,"amplitude":0.024413,"askPrice":120.66,"askSize":100,"bidPrice":120.65,"bidSize":18,"shortable":3,"etf":0,"ttmEps":6.422841,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":696056400000,"exchange":"NASDAQ","adjPreClose":119.61,"dividendRate":0.026025,"preHourTrading":{"tag":"盘前","latestPrice":122.03,"preClose":119.61,"latestTime":"09:29 EST","volume":7822,"amount":950301.11582,"timestamp":1765808999999},"postHourTrading":{"tag":"盘后","latestPrice":120.4,"preClose":120.4,"latestTime":"19:59 EST","volume":487119,"amount":58649055.4518,"timestamp":1765587571432},"volumeRatio":0.5566,"impliedVol":0.2938,"impliedVolPercentile":0.264},"requestUrl":"/m/hq/s/GILD/tweets","defaultTab":"tweets","newsList":[{"id":"1132993871","title":"吉利德科学针对HIV治疗的比克替普和莱那替韦单片疗法在第三阶段ARTISTRY-2试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1132993871","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132993871?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:32","pubTimestamp":1765805534,"startTime":"0","endTime":"0","summary":"吉利德科学针对HIV治疗的比克替普和莱那替韦单片疗法在第三阶段ARTISTRY-2试验中达到主要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU0889565916.HKD","LU1571399168.USD","BK4568","IE00BSNM7G36.USD","BK4550","LU0234570918.USD","LU1839511570.USD","SG9999015978.USD","BK4588","BK4566","LU0109394709.USD","GILD","LU0823416689.USD","IE00BKVL7J92.USD","LU0320765992.SGD","BK4585","LU1430594728.SGD","LU1674673691.USD","IE00B19Z3581.USD","LU2324357040.USD","SG9999015945.SGD","LU2089984988.USD","LU2087621335.USD","BK4532","LU0114720955.EUR","LU0289739699.SGD","SG9999015952.SGD","LU1066051498.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1778281490.HKD","SG9999015986.USD","IE00B3T34201.USD","LU1066053197.SGD","LU2468319806.SGD","IE0002270589.USD","LU0882574055.USD","IE00B19Z3B42.SGD","BK4583","BK4139","LU1585245621.USD","BK4578","LU0058720904.USD"],"gpt_icon":0},{"id":"1123601921","title":"吉利德科学 - 中期分析显示，Domvanalimab与Zimberelimab及化疗的组合相较于Nivolumab与化疗并未改善总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1123601921","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123601921?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:29","pubTimestamp":1765546157,"startTime":"0","endTime":"0","summary":"吉利德科学 - 中期分析显示，Domvanalimab与Zimberelimab及化疗的组合相较于Nivolumab与化疗并未改善总生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IE00B19Z3581.USD","SG9999015978.USD","GILD","LU0320765992.SGD","BK4550","LU0823416689.USD","LU1778281490.HKD","LU2087621335.USD","LU0234570918.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1571399168.USD","LU0114720955.EUR","BK4139","LU0882574055.USD","LU0889565916.HKD","LU1430594728.SGD","LU0058720904.USD","BK4578","SG9999015945.SGD","LU0109394709.USD","BK4585","BK4588","IE00B19Z3B42.SGD","SG9999015952.SGD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1839511570.USD","BK4566","LU1674673691.USD","LU2089984988.USD","BK4583","BK4532","LU1585245621.USD","IE0002270589.USD","LU2324357040.USD","BK4568","LU1066051498.USD","SG9999015986.USD","IE00BSNM7G36.USD","LU0289739699.SGD","IE00BKVL7J92.USD","LU1674673428.USD"],"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","IE00B7SZL793.SGD","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z4B17.USD","SG9999015945.SGD","BK4588","SG9999015978.USD","IE0002270589.USD","PFS","IE00B19Z3581.USD","CRS","IE00B7SZLL34.SGD","LU0289739699.SGD","ORR","LU0823416689.USD","KOL","LU1430594728.SGD","IE00B19Z3B42.SGD","BK4568","OS","BK4097","IE00B66KJ199.SGD","LU1066051498.USD","LU1674673691.USD","BK4195","LU1839511570.USD","GILD","SG9999015952.SGD","BK4550","CR","BK4139","LU0109394709.USD","BK4109","BK4566","LU1674673428.USD","ASH","BK4578","LU0882574055.USD","SG9999015986.USD","LU0234570918.USD","BK4532","IE00BZ1G4Q59.USD","LU1585245621.USD","IE00B3T34201.USD","BK4585","LU1778281490.HKD","BK4187"],"gpt_icon":0},{"id":"1151810716","title":"Aspen Neuroscience：C轮融资由Orbimed、Arch Venture Partners等共同牵头，S32、Axon Ventures、Kite等参与投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1151810716","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151810716?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:19","pubTimestamp":1763641183,"startTime":"0","endTime":"0","summary":"Aspen Neuroscience：C轮融资由Orbimed、Arch Venture Partners等共同牵头，S32、Axon Ventures、Kite等参与投资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0889565916.HKD","LU1778281490.HKD","SG9999015945.SGD","LU1066053197.SGD","LU1066051498.USD","BK4550","LU0882574055.USD","SG9999015986.USD","BK4532","BK4588","IE00B19Z3B42.SGD","LU0234570918.USD","LU1430594728.SGD","GILD","LU1674673428.USD","LU2089984988.USD","BK4139","SG9999015978.USD","IE00B19Z3581.USD","LU2324357040.USD","IE00BZ1G4Q59.USD","BK4568","LU0058720904.USD","LU2468319806.SGD","BK4585","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1585245621.USD","BK4578","LU0823416689.USD","SG9999015952.SGD","BK4566","LU1674673691.USD","BK4583","IE0002270589.USD","IE00B3T34201.USD","LU0289739699.SGD","LU2087621335.USD","IE00BKVL7J92.USD","LU0109394709.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"1104987976","title":"Aspen Neuroscience 宣布1.15亿美元C轮融资以加速个性化细胞治疗项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1104987976","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104987976?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:17","pubTimestamp":1763641028,"startTime":"0","endTime":"0","summary":"Aspen Neuroscience 宣布完成1.15亿美元的C轮融资，旨在加速其个性化细胞治疗项目的发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4583","LU0114720955.EUR","BK4585","GILD","LU0889565916.HKD","LU2087621335.USD","BK4550","LU1778281490.HKD","SG9999015952.SGD","BK4578","LU2468319806.SGD","LU0823416689.USD","IE0002270589.USD","LU0058720904.USD","SG9999015978.USD","LU1839511570.USD","LU0109394709.USD","LU2089984988.USD","IE00B3T34201.USD","LU1066051498.USD","LU1674673428.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE00BKVL7J92.USD","BK4532","LU0882574055.USD","LU1674673691.USD","LU1571399168.USD","BK4568","SG9999015945.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","BK4139","LU0234570918.USD","LU0320765992.SGD","LU2324357040.USD","BK4588","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4566","LU1585245621.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1142384908","title":"吉利德科学更新ASCENT-07三期研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1142384908","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142384908?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:10","pubTimestamp":1763572211,"startTime":"0","endTime":"0","summary":"11月7日 - 吉利德科学公司发布了其ASCENT-07三期研究的更新：该研究未能达到无病进展生存期的主要终点；安全性资料与之前对Trodelvy乳腺癌的研究一致，且在该患者群体中未发现新的安全性信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1571399168.USD","LU1585245621.USD","LU2089984988.USD","LU0109394709.USD","LU0289739699.SGD","BK4139","LU1430594728.SGD","LU1674673428.USD","IE00B3T34201.USD","LU2087621335.USD","SG9999015978.USD","BK4578","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4550","BK4588","IE00BSNM7G36.USD","LU1674673691.USD","BK4585","SG9999015945.SGD","IE0002270589.USD","BK4568","BK4532","LU0114720955.EUR","GILD","IE00B19Z3B42.SGD","LU1778281490.HKD","SG9999015952.SGD","LU2324357040.USD","SG9999015986.USD","IE00BKVL7J92.USD","LU0882574055.USD","BK4566","LU0234570918.USD","LU0823416689.USD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU1066051498.USD","LU1839511570.USD","LU2468319806.SGD","BK4583","IE00B19Z3581.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"1100305925","title":"吉利德科学 - 泰尔曼将于12月5日起不再担任公司事务和总法律顾问执行副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1100305925","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100305925?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:34","pubTimestamp":1763559269,"startTime":"0","endTime":"0","summary":"吉利德科学 - 泰尔曼将于12月5日起不再担任公司事务和总法律顾问执行副总裁","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU0882574055.USD","BK4566","LU2089984988.USD","LU1674673691.USD","LU0114720955.EUR","LU1066053197.SGD","GILD","BK4583","IE00B7SZLL34.SGD","LU0289739699.SGD","SG9999015986.USD","BK4578","IE00BZ1G4Q59.USD","LU0109394709.USD","BK4588","LU1839511570.USD","SG9999015952.SGD","LU1674673428.USD","LU0889565916.HKD","SG9999015978.USD","BK4532","IE00B19Z3B42.SGD","BK4550","LU1066051498.USD","LU1778281490.HKD","LU0320765992.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","LU0823416689.USD","BK4585","LU0234570918.USD","LU1571399168.USD","LU2087621335.USD","LU1585245621.USD","BK4139","LU2324357040.USD","SG9999015945.SGD","IE0002270589.USD","BK4568","IE00BSNM7G36.USD","LU0058720904.USD","IE00BKVL7J92.USD","LU1430594728.SGD"],"gpt_icon":0},{"id":"1188771558","title":"吉利德科学的单片剂方案在III期ARTISTRY-1试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1188771558","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188771558?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:31","pubTimestamp":1763040716,"startTime":"0","endTime":"0","summary":"吉利德科学的单片剂方案Bictegravir和Lenacapavir用于HIV-1治疗在III期ARTISTRY-1试验中达到了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0234570918.USD","LU1778281490.HKD","LU1839511570.USD","IE00BKVL7J92.USD","BK4550","LU0109394709.USD","LU2089984988.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU1066051498.USD","SG9999015978.USD","BK4585","LU0882574055.USD","IE00B19Z3B42.SGD","BK4139","BK4566","LU0289739699.SGD","LU0058720904.USD","BK4588","LU2468319806.SGD","LU1430594728.SGD","BK4578","LU0114720955.EUR","IE00BZ1G4Q59.USD","LU1585245621.USD","LU2324357040.USD","LU0320765992.SGD","LU1674673691.USD","LU1571399168.USD","BK4532","LU1066053197.SGD","SG9999015952.SGD","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU1674673428.USD","IE00BSNM7G36.USD","BK4568","LU2087621335.USD","BK4583","LU0823416689.USD","SG9999015945.SGD","SG9999015986.USD"],"gpt_icon":0},{"id":"1157913444","title":"吉利德科学首席财务官表示公司将继续积极开展业务发展，包括许可和并购","url":"https://stock-news.laohu8.com/highlight/detail?id=1157913444","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157913444?lang=zh_cn&edition=full","pubTime":"2025-11-11 00:35","pubTimestamp":1762792519,"startTime":"0","endTime":"0","summary":"吉利德科学首席财务官表示公司将继续积极开展业务发展，包括许可和并购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4583","LU1674673691.USD","LU2468319806.SGD","LU1430594728.SGD","LU2089984988.USD","BK4566","LU2087621335.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU0058720904.USD","SG9999015978.USD","IE00B19Z3581.USD","BK4532","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU1585245621.USD","LU1571399168.USD","LU1066051498.USD","LU2324357040.USD","BK4585","IE0002270589.USD","LU0889565916.HKD","BK4588","LU1066053197.SGD","LU1839511570.USD","BK4550","IE00BSNM7G36.USD","LU0882574055.USD","IE00B3T34201.USD","BK4139","LU1674673428.USD","LU0289739699.SGD","SG9999015986.USD","BK4578","IE00BKVL7J92.USD","LU0114720955.EUR","LU0823416689.USD","LU1778281490.HKD","SG9999015945.SGD","GILD","SG9999015952.SGD","BK4568"],"gpt_icon":0},{"id":"1145102354","title":"吉利德科学首席财务官表示医保改革对艾滋病业务影响约为9亿美元，整体业务影响达12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145102354","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145102354?lang=zh_cn&edition=full","pubTime":"2025-11-11 00:13","pubTimestamp":1762791201,"startTime":"0","endTime":"0","summary":"吉利德科学首席财务官表示，医保改革对艾滋病业务的影响约为9亿美元，整体业务的影响则达到12亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","LU1430594728.SGD","IE00B19Z3581.USD","LU2468319806.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU1066053197.SGD","BK4578","LU1571399168.USD","LU2089984988.USD","LU0823416689.USD","BK4532","IE00B3T34201.USD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU0882574055.USD","LU2087621335.USD","LU1839511570.USD","IE00BKVL7J92.USD","LU1674673428.USD","SG9999015945.SGD","LU0289739699.SGD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU1066051498.USD","IE0002270589.USD","BK4550","IE00B19Z3B42.SGD","LU1585245621.USD","IE00BSNM7G36.USD","LU0058720904.USD","LU1674673691.USD","LU2324357040.USD","SG9999015952.SGD","LU0114720955.EUR","SG9999015978.USD","SG9999015986.USD","GILD","BK4583"],"gpt_icon":0},{"id":"2582862418","title":"吉利德：Trop2 ADC一线治疗HR+/HER2-乳腺三期临床失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862418","media":"医药笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582862418?lang=zh_cn&edition=full","pubTime":"2025-11-08 09:31","pubTimestamp":1762565499,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年11月7日，吉利德宣布Trop2 ADC新药Trodelvy对比化疗一线治疗内分泌治疗后HR+/HER2-乳腺癌的三期临床ASCENT-07没有达到PFS主要终点，关键次要终点OS尚未成熟，但观察到获益趋势，研究将继续进行以评估OS数据。Trodelvy一线治疗三阴乳腺癌已经递交上市申请。总结吉利德Trodelvy为全球首款Trop2 ADC，但作为上一代ADC在适应症拓展的道路上充满曲折，先后在非小细胞肺癌、尿路上皮癌失败，此次HR+/HER2-乳腺癌又错失PFS终点，仅守住三阴乳腺癌这一阵地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093356a6e9fd53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4583","LU1674673691.USD","LU2468319806.SGD","LU1430594728.SGD","BK4231","LU2089984988.USD","ADC","BK4566","LU2087621335.USD","IE00B7SZLL34.SGD","LU0109394709.USD","LU0058720904.USD","BK4203","SG9999015978.USD","IE00B19Z3581.USD","BK4532","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU1585245621.USD","LU1571399168.USD","LU1066051498.USD","LU2324357040.USD","BK4585","IE0002270589.USD","LU0889565916.HKD","BK4588","LU1066053197.SGD","LU1839511570.USD","BK4550","BK4080","IE00BSNM7G36.USD","LU0882574055.USD","IE00B3T34201.USD","BK4139","LU1674673428.USD","LU0289739699.SGD","HR","BK4225","SG9999015986.USD","BK4578","IE00BKVL7J92.USD","LU0114720955.EUR","LU0823416689.USD","LU1778281490.HKD","SG9999015945.SGD","GILD","SG9999015952.SGD","BK4568"],"gpt_icon":0},{"id":"1152764069","title":"吉利德：预计2024年第四季度可享受4.5亿美元的所得税优惠，同时减少对应的5.3亿美元未确认税收优惠","url":"https://stock-news.laohu8.com/highlight/detail?id=1152764069","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152764069?lang=zh_cn&edition=full","pubTime":"2025-11-08 05:13","pubTimestamp":1762549994,"startTime":"0","endTime":"0","summary":"吉利德：预计2024年第四季度可享受4.5亿美元的所得税优惠，同时减少对应的5.3亿美元未确认税收优惠。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4583","LU0114720955.EUR","BK4585","GILD","LU0889565916.HKD","LU2087621335.USD","BK4550","LU1778281490.HKD","SG9999015952.SGD","BK4578","LU2468319806.SGD","LU0823416689.USD","IE0002270589.USD","LU0058720904.USD","SG9999015978.USD","LU1839511570.USD","LU0109394709.USD","LU2089984988.USD","IE00B3T34201.USD","LU1066051498.USD","LU1674673428.USD","IE00B19Z3581.USD","LU1430594728.SGD","IE00BKVL7J92.USD","BK4532","LU0882574055.USD","LU1674673691.USD","LU1571399168.USD","BK4568","SG9999015945.SGD","SG9999015986.USD","IE00B7SZLL34.SGD","BK4139","LU0234570918.USD","LU0320765992.SGD","LU2324357040.USD","BK4588","IE00B19Z3B42.SGD","LU0289739699.SGD","BK4566","LU1585245621.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1184501887","title":"吉利德科学：10月与税务机关达成与前一年法律实体重组相关的和解 - 文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184501887?lang=zh_cn&edition=full","pubTime":"2025-11-08 05:13","pubTimestamp":1762549993,"startTime":"0","endTime":"0","summary":"吉利德科学：10月与税务机关达成与前一年法律实体重组相关的和解 - 文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4566","LU1066053197.SGD","BK4550","IE00BKVL7J92.USD","LU0109394709.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","IE00BSNM7G36.USD","SG9999015945.SGD","LU1430594728.SGD","LU0114720955.EUR","LU0823416689.USD","LU0889565916.HKD","BK4578","BK4139","LU1066051498.USD","IE00B19Z3B42.SGD","LU0234570918.USD","BK4588","LU1839511570.USD","LU1571399168.USD","LU2089984988.USD","BK4583","LU1585245621.USD","IE00B3T34201.USD","BK4568","LU1778281490.HKD","SG9999015978.USD","SG9999015986.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","BK4585","LU0289739699.SGD","LU1674673428.USD","LU0058720904.USD","LU2087621335.USD","GILD","LU2468319806.SGD","LU0320765992.SGD","LU0882574055.USD","LU1674673691.USD","IE00B19Z3581.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"1157980952","title":"吉利德科学股价下跌2.2%，乳腺癌药物未达晚期研究主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1157980952","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157980952?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:59","pubTimestamp":1762527560,"startTime":"0","endTime":"0","summary":"吉利德科学股价下跌2.2%，乳腺癌药物未达晚期研究主要目标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU1430594728.SGD","IE00B7SZLL34.SGD","BK4139","BK4550","SG9999015945.SGD","BK4532","IE00B19Z3581.USD","BK4566","BK4588","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","BK4583","LU1674673428.USD","SG9999015986.USD","GILD","LU0882574055.USD","IE00B19Z3B42.SGD","LU1571399168.USD","SG9999015952.SGD","LU1585245621.USD","LU0889565916.HKD","LU1839511570.USD","LU0109394709.USD","BK4578","LU2087621335.USD","LU2089984988.USD","IE00BKVL7J92.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0114720955.EUR","LU2468319806.SGD","LU0823416689.USD","LU1674673691.USD","LU1778281490.HKD","LU0234570918.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"1160960792","title":"吉利德：安全性特征与之前Trodelvy乳腺癌研究一致，未在该患者群体中发现新的安全性信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1160960792","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160960792?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:31","pubTimestamp":1762522292,"startTime":"0","endTime":"0","summary":"吉利德：安全性特征与之前Trodelvy乳腺癌研究一致，未在该患者群体中发现新的安全性信号","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","BK4583","LU0109394709.USD","LU0823416689.USD","GILD","LU2324357040.USD","LU1066053197.SGD","LU1674673428.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","BK4566","SG9999015978.USD","BK4139","IE00B7SZLL34.SGD","BK4568","LU0114720955.EUR","LU1839511570.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU2087621335.USD","IE00B3T34201.USD","LU1778281490.HKD","BK4532","BK4550","LU2089984988.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0320765992.SGD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015945.SGD","SG9999015986.USD","SG9999015952.SGD","IE0002270589.USD","LU1066051498.USD","LU0234570918.USD","BK4588","LU1674673691.USD","LU1585245621.USD","LU0058720904.USD","BK4585","BK4578","IE00B19Z3581.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"1115807732","title":"吉利德：Livdelzi独家新数据凸显其作为PBC患者有效且耐受良好选择的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1115807732","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115807732?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:02","pubTimestamp":1762520536,"startTime":"0","endTime":"0","summary":"吉利德：Livdelzi独家新数据凸显其作为PBC患者有效且耐受良好选择的潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","LU0109394709.USD","BK4583","BK4578","SG9999015986.USD","BK4588","LU2324357040.USD","LU1674673428.USD","IE00B19Z3B42.SGD","LU0823416689.USD","BK4550","BK4585","LU0114720955.EUR","LU1066051498.USD","LU0882574055.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","BK4566","IE00B19Z3581.USD","LU2089984988.USD","BK4568","IE00B3T34201.USD","SG9999015952.SGD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066053197.SGD","LU0289739699.SGD","LU1839511570.USD","GILD","LU1778281490.HKD","SG9999015978.USD","LU1571399168.USD","BK4532","IE00B7SZLL34.SGD","LU1430594728.SGD","LU1674673691.USD","LU1585245621.USD","BK4139","LU2468319806.SGD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015945.SGD","LU2087621335.USD"],"gpt_icon":0},{"id":"1188865722","title":"吉利德的Livdelzi®在原发性胆汁性胆管炎（PBC）中显示持续疗效，提供碱性磷酸酶（Alp）降低、缓解瘙痒及减缓疾病进展的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1188865722","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188865722?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:01","pubTimestamp":1762520508,"startTime":"0","endTime":"0","summary":"吉利德的Livdelzi®在原发性胆汁性胆管炎（PBC）中显示出持续的疗效，能够降低碱性磷酸酶（Alp）水平，缓解瘙痒感，并有潜力减缓疾病的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4139","LU0889565916.HKD","IE00BSNM7G36.USD","LU0320765992.SGD","BK4583","LU0823416689.USD","LU2324357040.USD","LU1674673428.USD","IE00B7SZLL34.SGD","GILD","BK4532","LU1839511570.USD","LU0882574055.USD","IE00B3T34201.USD","BK4585","SG9999015952.SGD","BK4550","BK4578","BK4588","IE00BKVL7J92.USD","LU0114720955.EUR","LU2087621335.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","SG9999015986.USD","LU2089984988.USD","LU0234570918.USD","LU0058720904.USD","BK4566","LU0289739699.SGD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1674673691.USD","SG9999015945.SGD","BK4568","LU1778281490.HKD","LU1066051498.USD","LU1430594728.SGD","IE0002270589.USD","SG9999015978.USD","IE00B19Z3581.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2581079810","title":"吉利德科学携两款亚洲首发展品亮相进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2581079810","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581079810?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:59","pubTimestamp":1762516799,"startTime":"0","endTime":"0","summary":"在第八届中国国际进口博览会（以下简称进博会）上，吉利德科学携多款产品亮相，其中包括两款亚洲首发产品：长效HIV暴露前预防药物Lenacapavir（来那帕韦）和原发性胆汁性胆管炎（PBC）新药Seladelpar，以及在华上市的13款创新药物等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073558461893.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073558461893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","LU1571399168.USD","LU1585245621.USD","LU2089984988.USD","LU0109394709.USD","LU0289739699.SGD","BK4139","LU1430594728.SGD","LU1674673428.USD","IE00B3T34201.USD","LU2087621335.USD","SG9999015978.USD","BK4578","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4550","BK4588","IE00BSNM7G36.USD","LU1674673691.USD","BK4585","SG9999015945.SGD","IE0002270589.USD","BK4568","BK4532","LU0114720955.EUR","GILD","IE00B19Z3B42.SGD","LU1778281490.HKD","SG9999015952.SGD","LU2324357040.USD","SG9999015986.USD","IE00BKVL7J92.USD","LU0882574055.USD","BK4566","LU0234570918.USD","LU0823416689.USD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU1066051498.USD","LU1839511570.USD","LU2468319806.SGD","BK4583","IE00B19Z3581.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2581777998","title":"（第八届进博会）跨国药企深耕进博会 加速创新成果落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777998","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581777998?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:40","pubTimestamp":1762353653,"startTime":"0","endTime":"0","summary":"中新社上海11月5日电(记者陈静)“过去七年，从展品到商品，再到临床广泛可及，进博会已成为创新药物加速惠及中国患者的重要催化平台。”诺华公司中国区副总裁，心血管、肾脏及代谢治疗领域兼创新患者服务负责人管宏5日对记者表示，得益于进博会的溢出效应，诺华公司多款心肾领域的创新药物实现首秀到落地的跨越。第八届中国国际进口博览会5日开幕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053556163538.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053556163538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ1G4Q59.USD","LU1778281490.HKD","BK1574","BK4568","IE00BSNM7G36.USD","LU0114720955.EUR","SG9999015978.USD","LU0234570918.USD","LU0882574055.USD","SG9999015986.USD","GILD","SG9999015945.SGD","IE0002270589.USD","PBC","LU0289739699.SGD","LU0823416689.USD","BK4550","BK4583","LU1066053197.SGD","BK4585","LU2089984988.USD","BK4139","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4532","IE00BKVL7J92.USD","LU1674673691.USD","BK4588","LU0320765992.SGD","IE00B19Z3B42.SGD","LU2324357040.USD","LU1571399168.USD","LU0109394709.USD","LU1430594728.SGD","BK4566","BK1161","LU1674673428.USD","LU1839511570.USD","LU1066051498.USD","BK4578","06978","LU2087621335.USD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","SG9999015952.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2581715385","title":"吉利德四赴进博会：全球首款长效HIV预防药亚洲首秀","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715385","media":"南方都市报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581715385?lang=zh_cn&edition=full","pubTime":"2025-11-04 13:24","pubTimestamp":1762233852,"startTime":"0","endTime":"0","summary":"从“展品”到“药品”，从“首展”到“首用”，吉利德科学借进博会“黄金跑道”持续跑出“中国速度”。11月展台现场，吉利德将首次在亚洲公开展示这一全新的HIV预防方案，并同步披露其在全球同步研发框架下中国参与项目的最新进展——10项肿瘤、6项非肿瘤研究中，90%的肿瘤项目已实现与全球“零时差”开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104132704a6df8bb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251104132704a6df8bb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","GILD","LU1674673691.USD","LU0114720955.EUR","BK4583","SG9999015978.USD","IE00B19Z3B42.SGD","PBC","LU0889565916.HKD","LU0882574055.USD","IE0002270589.USD","LU1674673428.USD","LU1066053197.SGD","LU1585245621.USD","LU2089984988.USD","SG9999015945.SGD","BK4568","LU1066051498.USD","BK4588","LU2087621335.USD","LU1778281490.HKD","LU0320765992.SGD","IE00BKVL7J92.USD","LU0289739699.SGD","BK4585","IE00B3T34201.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4139","BK4550","LU0109394709.USD","LU1839511570.USD","SG9999015986.USD","IE00B19Z3581.USD","LU1430594728.SGD","BK4566","LU0823416689.USD","BK4578","BK4532","LU0058720904.USD","LU2324357040.USD","LU2468319806.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":-0.0243},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.3035}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.575758,"avgChangeRate":0.041534},{"month":2,"riseRate":0.411765,"avgChangeRate":0.007165},{"month":3,"riseRate":0.529412,"avgChangeRate":-0.009708},{"month":4,"riseRate":0.529412,"avgChangeRate":0.011973},{"month":5,"riseRate":0.558824,"avgChangeRate":0.0204},{"month":6,"riseRate":0.647059,"avgChangeRate":0.025673},{"month":7,"riseRate":0.558824,"avgChangeRate":0.01609},{"month":8,"riseRate":0.558824,"avgChangeRate":0.033158},{"month":9,"riseRate":0.558824,"avgChangeRate":0.031157},{"month":10,"riseRate":0.529412,"avgChangeRate":0.003173},{"month":11,"riseRate":0.647059,"avgChangeRate":0.039736},{"month":12,"riseRate":0.382353,"avgChangeRate":0.009567}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}